Home

The Korea Herald

Latest news

Most Popular

  1. 1

    1 in 3 Koreans live alone, family types becoming diverse

    1 in 3 Koreans live alone, family types becoming diverse
  2. 2

    Korea, Japan finance chiefs vow to tame rampant FX market volatility

    Korea, Japan finance chiefs vow to tame rampant FX market volatility
  3. 3

    K-pop group's manager dismissed for setting up spycam in theater dressing room

    K-pop group's manager dismissed for setting up spycam in theater dressing room
  4. 4

    K-pop singer lost consciousness after being hit by foul ball, cancels show

    K-pop singer lost consciousness after being hit by foul ball, cancels show
  5. 5

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  1. 6

    Korean Muslim YouTuber's plan to build mosque in Incheon goes viral

    Korean Muslim YouTuber's plan to build mosque in Incheon goes viral
  2. 7

    Why is Apple Pay struggling to get purchase in Korea?

    Why is Apple Pay struggling to get purchase in Korea?
  3. 8

    Yoon's office denies considering liberal figures for key posts

    Yoon's office denies considering liberal figures for key posts
  4. 9

    Seoul says Fu Bao loan 'not going to happen'

    Seoul says Fu Bao loan 'not going to happen'
  5. 10

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
지나쌤

Celltrion's operating profit up 89% in Q3

By Yonhap

Published : Nov. 8, 2017 - 15:03

    • Link copied

Celltrion Inc., a South Korean biopharmaceutical firm, said Wednesday that its operating profit soared 89.3 percent on-year in the third quarter, helped by robust sales of its biosimilar Remsima in overseas markets.

Operating income came to 140 billion won (US$125.8 million) in the July-September period, compared with 74 billion won logged the previous year, the company said in a regulatory filing.

Sales also jumped 37.9 percent on-year to 232 billion won, with net profit also almost doubling to 114 billion won over the cited period.

(Herald DB) (Herald DB)


The stronger bottom line came on the back of hefty sales of Remsima in overseas markets, both in Europe and the United States.

"In addition to increased sales in overseas markets, improved yields at biomedicine factories have resulted in positive earnings," said a company official asked not to be named.

Remsima is an identical copy of Janssen Biotech, Inc.'s Remicade, and is effective in treating various diseases from rheumatoid arthritis to Crohn's disease. In the U.S. market, Remsima went on sale during the fourth quarter of last year under the name Inflectra by Pfizer Inc.

The company also began selling another biosimilar drug Truxima in Germany and in Britain following approval from European regulators. (Yonhap)

More from Headlines